Cardiac ion channel proteins are the targets for antiarrhythmic drug action. This Project will integrate functional analysis (voltage clamp of ionic currents) and molecular biological techniques to identify blocking mechanisms and channel protein binding domains for antiarrhythmic agents which block potassium channels. Experiments will utilize both native potassium channels in isolated cardiac cells as well as channels cloned from mammalian (including human) heart. Potassium currents will be measured in isolation and without contamination from other ionic currents in the exogenous expression systems, Xenopus oocytes and mouse fibroblasts, which will be used in this Project. The determinants of the interactions of drugs with open channels, including channel gating, voltage-dependence and ion permeation, and with inactivated channels will be tested experimentally and the results used to refine models of drug inhibition of ion currents. Site-directed channel protein modifications and the expression of heteromeric channels will be used to elucidate the molecular determinants of drug action, including identification of drug binding loci on ion channels. The information gained here will feed back to other Projects in this Program which evaluate drug actions in other systems. This Project will improve our understanding of the mechanisms of antiarrhythmic drug action and may thereby point to strategies which will be useful in the development of newer and safer compounds.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
1P01HL046681-01A1
Application #
3844967
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Yang, Tao; Smith, Jarrod A; Leake, Brenda F et al. (2013) An allosteric mechanism for drug block of the human cardiac potassium channel KCNQ1. Mol Pharmacol 83:481-9
Hayashi, Kenshi; Shuai, Wen; Sakamoto, Yuichiro et al. (2010) Trafficking-competent KCNQ1 variably influences the function of HERG long QT alleles. Heart Rhythm 7:973-80
Yang, Tao; McBride, Brian F; Leake, Brenda F et al. (2010) Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. Br J Pharmacol 161:1023-33
Potet, Franck; Petersen, Christina I; Boutaud, Olivier et al. (2009) Genetic screening in C. elegans identifies rho-GTPase activating protein 6 as novel HERG regulator. J Mol Cell Cardiol 46:257-67
Yang, Tao; Kanki, Hideaki; Zhang, Wei et al. (2009) Probing the mechanisms underlying modulation of quinidine sensitivity to cardiac I(Ks) block by protein kinase A-mediated I(Ks) phosphorylation. Br J Pharmacol 157:952-61
Stepanovic, Svetlana Z; Potet, Franck; Petersen, Christina I et al. (2009) The evolutionarily conserved residue A653 plays a key role in HERG channel closing. J Physiol 587:2555-66
Yang, Tao; Chung, Seo-Kyung; Zhang, Wei et al. (2009) Biophysical properties of 9 KCNQ1 mutations associated with long-QT syndrome. Circ Arrhythm Electrophysiol 2:417-26
Grueter, Chad E; Abiria, Sunday A; Wu, Yunji et al. (2008) Differential regulated interactions of calcium/calmodulin-dependent protein kinase II with isoforms of voltage-gated calcium channel beta subunits. Biochemistry 47:1760-7
Baudenbacher, Franz; Schober, Tilmann; Pinto, Jose Renato et al. (2008) Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest 118:3893-903
Makita, Naomasa; Behr, Elijah; Shimizu, Wataru et al. (2008) The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest 118:2219-29

Showing the most recent 10 out of 171 publications